BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Elinogrel: Suspended Phase III enrollment

Novartis suspended the placebo-controlled Phase III ECLIPSE trial to evaluate elinogrel in patients with chronic coronary heart disease to prioritize development of the compound in acute coronary syndrome (ACS). The...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >